Shares of US biopharma CorMedix (Nasdaq: CRMD) rose as much as 18% ad closed up 6.4% at $3.33 yesterday, after it revealed that the US Food and Drug Administration (FDA) has approved its DefenCath (taurolidine and heparin).
DefenCath is a catheter lock solution (CLS) and has been authorized to reduce the incidence of catheter-related bloodstream infections (CRBSIs) for the limited population of adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC).
The company noted that DefenCath is the first and only FDA-approved antimicrobial CLS in the USA and was shown to reduce the risk of CRBSIs by up to 71% in a Phase III clinical study.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze